SCHEMBL4334635

SCHEMBL4334635

COc1c(C(=O)NCc2ccoc2)ccc2[nH]nc(-c3ccc4ccccc4c3)c12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.39
MAPK1 P28482 1/20 0.39
CDK4 P11802 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CDK2 P24941 1/20 0.38
CCND3 P30281 1/20 0.38
KDR P35968 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ROCK2 O75116 5/20 0.38
RET P07949 1/20 0.37
LRRK2 Q5S007 2/20 0.37
CSNK1D P48730 1/20 0.37
ROCK1 Q13464 3/20 0.37
MAPT P10636 1/20 0.36
PRKACA P17612 1/20 0.36
PRKACG P22612 1/20 0.36
PRKACB P22694 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856935 0.86 SMN1; SMN2 (0.54) SMN1; SMN2ROCK2ROCK1MAPTPRKACA
SCHEMBL4341196 0.85 MEN1 (0.49) MAPK1SMN1; SMN2MAPT
SCHEMBL4332984 0.85 KDM4E (0.40) KDRSMN1; SMN2MAPT
SCHEMBL4341067 0.84 RAB9A (0.46) MAPK1SMN1; SMN2MAPT
SCHEMBL4333960 0.84 MAPK10 (0.37) EGLN1MAPK1SMN1; SMN2RETLRRK2
SCHEMBL4333025 0.83 ALDH1A1 (0.41) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL4334432 0.83 MEN1 (0.45) EGLN1MAPK1SMN1; SMN2ROCK2ROCK1
SCHEMBL13635804 0.82 KDR (0.37) EGLN1MAPK1CDK4CCNA2CCND1
SCHEMBL13635355 0.81 KDM4E (0.42) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL4348178 0.81 LMNA (0.45) MAPK1CDK4CCNA2CCND1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 EGLN1 1226/4885MAPK1 1/4885CDK4 103/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 EGLN1 1226/4885MAPK1 1/4885CDK4 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.